Ocular Manifestations in Rheumatic Dise… | Clinical Trial

Key information

Conditions

Uveitis Amaurosis Fugax Arterial Occlusive Diseases Blindness Cardiovascular Diseases Chorioretinitis Choroid Diseases Choroid Hemorrhage Choroiditis Conjunctival Diseases Conjunctivitis Corneal Diseases Cranial Nerve Diseases Dry Eye Syndromes Embolism and Thrombosis Eye Diseases Eye Hemorrhage Eye Manifestations Hemorrhage Iridocyclitis Iris Diseases Keratitis Keratoconjunctivitis Keratoconjunctivitis Sicca Lacrimal Apparatus Diseases Macular Degeneration Macular Edema Nervous System Diseases Neurologic Manifestations Optic Nerve Diseases Optic Neuritis Orbital Diseases Panuveitis Papilledema Pathologic Processes Pathological Conditions, Signs and Symptoms Retinal Artery Occlusion Retinal Degeneration Retinal Diseases Retinal Vein Occlusion Retinitis Scleral Diseases Scleritis Sensation Disorders Signs and Symptoms Thrombosis Uveal Diseases Uveitis, Anterior Uveitis, Posterior Vascular Diseases Venous Thrombosis Vision Disorders Xerophthalmia

Sex eligibility

All sexes

Study type

Observational

About this study

For the purposes of determining the prevalence of ocular complications in inflammatory rheumatic diseases, the following search terms were used: conjunctivitis, keratoconjunctivitis sicca, xerophthalmia, uveitis, eye hemorrhage, optic neuritis, papilledema, orbital disease, retinal artery/vein occlusion, macular edema, retinitis, chorioretinitis, scleritis, iridocyclitis, choroid hemorrhage, blindness and amaurosis fugax.

These terms were searched in the context of a corresponding inflammatory disease on Medline, Cochrane and Web of Science from their inception (1966, 1991 and 1990 respectively) until the point of study completion.

Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in an inflammatory rheumatic disease. Studies were excluded if they were review articles, case reports where all patients experienced the same ocular comorbidity, if different comorbidities were not grouped independently, and if the study reported on fewer than 20 patients. When the same study cohort was used in more than one analysis, the most recent or largest sample-size study was included. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used to assess the quality of cohort, case-control, and cross-sectional studies.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in inflammatory rheumatic disease

Exclusion criteria

review articles,
case reports where all patients experienced the same ocular comorbidity
if different comorbidities were not grouped independently
if the study reported on fewer than 20 patients

Treatment and study plan

No intervention used

Other

no intervention used

Primary outcomes

Prevalence of ocular manifestations of inflammatory rheumatic diseases

Time frame: data is collected once per year up to 2020

Prevalence of ocular manifestations of inflammatory rheumatic diseases

Sponsors and collaborators

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Other

Registry information

Official study title

Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases

Important dates

Study start: 2013
Primary completion: 2021
Study completion: 2021
First posted: Nov 27, 2018
Registry last updated: Apr 12, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed